NCT04656470

Neuroimaging Study of Dexmedetomidine-Induced Analgesia

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.

Detailed description

In this trial, participants will be given dexmedetomidine using a single-arm study design. fMRI will be conducted during this time. Cognitive assessments and pain monitoring will be administered at various points before and after dexmedetomidine is administered.

Conditions

• Analgesia
• Anesthesia

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.

Timeline

• Start date: 2022-03-04
• Primary completion: 2025-05-27
• Completion: 2025-05-27
• First posted: 2020-12-07
• Last updated: 2025-12-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study